denileukin diftitox (E7777)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Jul 1, 2011 → Jan 1, 2016
NCT ID
NCT01401530About denileukin diftitox (E7777)
denileukin diftitox (E7777) is a phase 1 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01401530. Target conditions include Peripheral T-Cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01401530 | Phase 1 | Completed |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma